Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.
Mol Pain. 2013 Feb 19;9:5. doi: 10.1186/1744-8069-9-5.
GTP cyclohydrolase 1 (GTP-CH1), the rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4), encoded by the GCH1 gene, has been implicated in the development and maintenance of inflammatory pain in rats. In humans, homozygous carriers of a "pain-protective" (PP) haplotype of the GCH1 gene have been identified exhibiting lower pain sensitivity, but only following pain sensitisation. Ex vivo, the PP GCH1 haplotype is associated with decreased induction of GCH1 after stimulation, whereas the baseline BH4 production is not affected. Contrary, loss of function mutations in the GCH1 gene results in decreased basal GCH1 expression, and is associated with DOPA-responsive dystonia (DRD). So far it is unknown if such mutations affect acute and inflammatory pain.
In the current study, we examined the involvement of the GCH1 gene in pain models using the hyperphenylalaninemia 1 (hph-1) mouse, a genetic model for DRD, with only 10% basal GTP-CH1 activity compared to wild type mice. The study included assays for determination of acute nociception as well as models for pain after sensitisation. Pain behavioural analysis of the hph-1 mice showed reduced pain-like responses following intraplantar injection of CFA, formalin and capsaicin; whereas decreased basal level of GTP-CH1 activity had no influence in naïve hph-1 mice on acute mechanical and heat pain thresholds. Moreover, the hph-1 mice showed no signs of motor impairment or dystonia-like symptoms.
In this study, we demonstrate novel evidence that genetic mutations in the GCH1 gene modulate pain-like hypersensitivity. Together, the present data suggest that BH4 is not important for basal heat and mechanical pain, but they support the hypothesis that BH4 plays a role in inflammation-induced hypersensitivity. Our studies suggest that the BH4 pathway could be a therapeutic target for the treatment of inflammatory pain conditions. Moreover, the hph-1 mice provide a valid model to study the consequence of congenital deficiency of GCH1 in painful conditions.
GTP 环水解酶 1(GTP-CH1)是四氢生物蝶呤(BH4)合成的限速酶,由 GCH1 基因编码,已被证明与大鼠炎症性疼痛的发生和维持有关。在人类中,已经确定 GCH1 基因的“疼痛保护”(PP)单倍型的纯合子携带者表现出较低的疼痛敏感性,但仅在疼痛敏化后。在体外,PP GCH1 单倍型与刺激后 GCH1 的诱导减少有关,而 BH4 的基础产量不受影响。相反,GCH1 基因的功能丧失突变导致基础 GCH1 表达减少,并与多巴反应性肌张力障碍(DRD)有关。到目前为止,尚不清楚这种突变是否会影响急性和炎症性疼痛。
在本研究中,我们使用高苯丙氨酸血症 1(hph-1)小鼠(DRD 的遗传模型)检查了 GCH1 基因在疼痛模型中的参与,与野生型小鼠相比,该模型的基础 GTP-CH1 活性仅为 10%。该研究包括用于确定急性痛觉的测定以及用于敏化后疼痛的模型。hph-1 小鼠的疼痛行为分析显示,在足底注射 CFA、福马林和辣椒素后,疼痛样反应减少;而在未致敏的 hph-1 小鼠中,基础 GTP-CH1 活性降低对急性机械和热痛阈值没有影响。此外,hph-1 小鼠没有运动障碍或肌张力障碍样症状。
在这项研究中,我们提供了新的证据,证明 GCH1 基因的遗传突变调节疼痛样过敏。总之,目前的数据表明,BH4 对基础热和机械痛不重要,但它们支持 BH4 在炎症诱导的过敏中的作用假说。我们的研究表明,BH4 途径可能是治疗炎症性疼痛的治疗靶点。此外,hph-1 小鼠为研究 GCH1 先天性缺乏在疼痛条件下的后果提供了有效模型。